Your browser doesn't support javascript.
loading
Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease.
Yau, Kevin; Kurtesi, Alexandra; Qi, Freda; Delgado-Brand, Melanie; Tursun, Tulunay R; Hu, Queenie; Dhruve, Miten; Kandel, Christopher; Enilama, Omosomi; Levin, Adeera; Jiang, Yidi; Hardy, W Rod; Yuen, Darren A; Perl, Jeffrey; Chan, Christopher T; Leis, Jerome A; Oliver, Matthew J; Colwill, Karen; Gingras, Anne-Claude; Hladunewich, Michelle A.
Afiliação
  • Yau K; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Kurtesi A; Division of Nephrology, Department of Medicine, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Qi F; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Delgado-Brand M; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Tursun TR; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Hu Q; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Dhruve M; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Kandel C; Division of Nephrology, Michael Garron Hospital, Toronto, ON, Canada.
  • Enilama O; Division of Infectious Diseases, Michael Garron Hospital, Toronto, ON, Canada.
  • Levin A; Division of Experimental Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
  • Jiang Y; British Columbia Provincial Renal Agency, Vancouver, BC, Canada.
  • Hardy WR; Centre for Clinical Trial Support, Sunnybrook Research Institute, Toronto, ON, Canada.
  • Yuen DA; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
  • Perl J; Division of Nephrology, Department of Medicine, Unity Health Toronto, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Chan CT; Division of Nephrology, Department of Medicine, Unity Health Toronto, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Leis JA; Division of Nephrology, Department of Medicine, University Health Network, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Oliver MJ; Division of Infectious Diseases, Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Colwill K; Division of Nephrology, Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Gingras AC; Ontario Renal Network, Toronto, ON, Canada.
  • Hladunewich MA; Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.
Nat Commun ; 14(1): 6041, 2023 09 27.
Article em En | MEDLINE | ID: mdl-37758707
ABSTRACT
Neutralization of Omicron subvariants by different bivalent vaccines has not been well evaluated. This study characterizes neutralization against Omicron subvariants in 98 individuals on dialysis or with a kidney transplant receiving the BNT162b2 (BA.4/BA.5) or mRNA-1273 (BA.1) bivalent COVID-19 vaccine. Neutralization against Omicron BA.1, BA.5, BQ.1.1, and XBB.1.5 increased by 8-fold one month following bivalent vaccination. In comparison to wild-type (D614G), neutralizing antibodies against Omicron-specific variants were 7.3-fold lower against BA.1, 8.3-fold lower against BA.5, 45.8-fold lower against BQ.1.1, and 48.2-fold lower against XBB.1.5. Viral neutralization was not significantly different by bivalent vaccine type for wild-type (D614G) (P = 0.48), BA.1 (P = 0.21), BA.5 (P = 0.07), BQ.1.1 (P = 0.10), nor XBB.1.5 (P = 0.10). Hybrid immunity conferred higher neutralizing antibodies against all Omicron subvariants. This study provides evidence that BNT162b2 (BA.4/BA.5) and mRNA-1273 (BA.1) induce similar neutralization against Omicron subvariants, even when antigenically divergent from the circulating variant.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina de mRNA-1273 contra 2019-nCoV / Falência Renal Crônica Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacina de mRNA-1273 contra 2019-nCoV / Falência Renal Crônica Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article